Cancer cell motility mechanisms

Cancer cell motility mechanisms is not a single molecule or receptor but rather refers to the collective cellular and molecular processes that enable cancer cells to move from their site of origin to invade surrounding tissues and metastasize to distant organs. These mechanisms involve complex signaling pathways (such as Rho GTPase/ROCK), cytoskeletal rearrangements (actin polymerization, myosin contractility), and responses to various migratory cues including chemotactic gradients, mechanical properties of the extracellular matrix, and electrical fields[1][2][4][5]. Key molecular players include RhoA/ROCK kinases, actin-binding proteins like cofilin, protein kinase D1 (PKD1), and others that regulate actin dynamics and focal adhesion turnover[2][4]. The process encompasses both mesenchymal-type movement—requiring degradation of extracellular matrix—and amoeboid-type movement—driven by cortical contractility allowing cells to squeeze through tissue spaces[2]. Because "cancer cell motility mechanisms" describes a set of biological processes rather than a discrete druggable target or receptor/enzyme/protein family member, it is not considered a canonical therapeutic target itself. Instead, individual molecules within these pathways may serve as specific targets for anti-metastatic therapies. Note: This entry is marked as incorrect for use as a canonical drug target because it does not refer to an individual molecule or protein but rather an entire class of cellular behaviors/processes. For structured data purposes in drug discovery databases or ontologies focused on molecular targets, this should be flagged accordingly.

Other names

Cell migration in cancerTumor cell motilityCancer cell migration mechanismsMetastatic cell movement